Status:
COMPLETED
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Swiss National Science Foundation
Conditions:
Liver Disease
Cirrhosis of the Liver
Eligibility:
All Genders
18+ years
Brief Summary
This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at...
Detailed Description
MER receptor tyrosine kinase (MERTK) signalling cascade becomes activated on monocytes/macrophages during disease progression of liver cirrhosis from Child Pugh A to B/C, corresponding to early stages...
Eligibility Criteria
Inclusion
- Patients with compensated or decompensated chronic liver disease
- Patients with acute- or acute-on-chronic chronic liver failure
- Controls with no liver disease
Exclusion
- Evidence of disseminated malignancy
Key Trial Info
Start Date :
August 27 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 10 2024
Estimated Enrollment :
277 Patients enrolled
Trial Details
Trial ID
NCT04116242
Start Date
August 27 2015
End Date
June 10 2024
Last Update
June 25 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Hepatology Department and Laboratory
Basel, Switzerland, 4031
2
Cantonal Hospital St. Gallen
Sankt Gallen, Switzerland, 9007
3
King's College Hospital, Institute of Liver studies
London, United Kingdom, SE5 9RS
4
St. Mary's Hospital, Imperial College London, Section of Hepatology
London, United Kingdom, W2 1PG